Investing.com - Summit Therapeutics (NASDAQ:SMMT) PLC reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Summit Therapeutics PLC announced earnings per share of $-0.140 on revenue of $220K. Analysts polled by Investing.com anticipated EPS of $-0.260 on revenue of $0.00.
Summit Therapeutics PLC shares are down 28.9% from the beginning of the year, still down 82.97% from its 52 week high of $5.79 set on November 17, 2021.
Summit Therapeutics PLC shares lost 3.32% in intra-day trade following the report.
Summit Therapeutics PLC follows other major Healthcare sector earnings this month
Summit Therapeutics PLC's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar